OPSEU/SEFPO Demands Immediate Termination of Grifols Plasma Contract After Safety Failures
Event summary
- OPSEU/SEFPO calls for immediate termination of Grifols' plasma collection contract after two donor deaths and 25 serious adverse reactions since 2018.
- Health Canada issued a non-compliance rating to Grifols following an inspection, leading to the company pausing all plasma collection in Canada as of August 14, 2026.
- Grifols facilities across multiple provinces received non-compliant ratings for improper donor screening and equipment maintenance issues.
- CBS workers secured a collective agreement ensuring new Ontario sites will be represented by OPSEU/SEFPO under a unified contract.
The big picture
The push to terminate Grifols' contract highlights ongoing tensions between public health priorities and privatization in Canada's blood services sector. The 2022 loophole that allowed CBS to partner with a for-profit entity has sparked backlash, reigniting debates over the Krever Inquiry's recommendations from the 1980s tainted blood scandal. This event underscores broader industry trends where cost-cutting privatization measures clash with public safety mandates.
What we're watching
- Regulatory Scrutiny
- The pace at which Health Canada will enforce stricter oversight on private plasma collection operations.
- Public vs. Private
- Whether Canadian Blood Services can sustain public trust while navigating privatization loopholes.
- Government Response
- How the Ontario government will address calls to permanently end for-profit plasma collection.
Related topics